TSHA Taysha Gene Therapies, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Taysha Gene Therapies, Inc. (TSHA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 19, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on March 19, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Taysha Gene Therapies, Inc. (TSHA) (SEC CIK 1806310), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New legal risk: SEC subpoenas in late 2024 investigating August 2023 PIPE and public offerings
- • Materially updated clinical risk: May 2025 Phase 1/2 REVEAL TSHA-102 data preliminary, may materially change as more patient data accrue
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Item 2.02 references an earnings release or financial report included as Exhibit 99.1
- • Filing clarifies the 8-K is furnished, not filed, limiting liability under Exchange Act Section 18
Quarterly Reports Archive10-Q
AI-powered analysis of Taysha Gene Therapies, Inc. (TSHA) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Taysha Gene Therapies, Inc. (TSHA) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $2.5M | $15.5M | $8.3M | $9.8M |
| Operating Income | -$162.4M | -$72.4M | -$91.5M | -$110.5M |
| Net Income | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| Op. Margin | -6492.7% | -468.8% | -1097.6% | -1130.6% |
| Net Margin | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Balance Sheet | ||||
| Total Assets | $126.3M | $172.7M | $160.4M | $343.3M |
| Equity | $949K | $74.9M | $71.5M | $246.9M |
| ROE | -17493.6% | -148.9% | -124.8% | -44.1% |
Source: XBRL financial data from Taysha Gene Therapies, Inc. (TSHA) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-K | Mar 19, 2026 | Dec 31, 2025 | — | |
8-K | Mar 19, 2026 | — | Analysis | — |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 12, 2025 | Jun 30, 2025 | — | |
10-Q | May 15, 2025 | Mar 31, 2025 | — | |
10-K | Feb 26, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 12, 2024 | Jun 30, 2024 | — | |
10-Q | May 14, 2024 | Mar 31, 2024 | — | |
10-K | Mar 19, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 14, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 16, 2022 | Mar 31, 2022 | — | |
10-K | Mar 31, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 16, 2021 | Jun 30, 2021 | — | |
10-Q | May 11, 2021 | Mar 31, 2021 | — | |
10-K | Mar 3, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 12, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest TSHA SEC filings in 2026?
Taysha Gene Therapies, Inc. (TSHA) has filed a 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on March 19, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TSHA file its most recent 10-K annual report?
Taysha Gene Therapies, Inc. (TSHA) filed its most recent 10-K annual report on March 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TSHA 10-Q quarterly reports?
Taysha Gene Therapies, Inc. (TSHA)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every TSHA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TSHA filed recently?
Taysha Gene Therapies, Inc. (TSHA)'s most recent 8-K was filed on March 19, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TSHA insider trading activity (Form 4)?
SignalX aggregates every TSHA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TSHA file with the SEC?
Taysha Gene Therapies, Inc. (TSHA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TSHA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Taysha Gene Therapies, Inc. (TSHA).
What is TSHA's SEC CIK number?
Taysha Gene Therapies, Inc. (TSHA)'s SEC CIK (Central Index Key) number is 1806310. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1806310 to look up all TSHA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TSHA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Taysha Gene Therapies, Inc. (TSHA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Taysha Gene Therapies, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 23+ filings.